The skin of an adult human contains about 20 billion memory T cells. Epithelial barrier tissues are infiltrated by a combination of resident and recirculating T cells in mice, but the relative proportions and functional activities of resident versus recirculating T cells have not been evaluated in human skin. We discriminated resident from recirculating T cells in human-engrafted mice and lymphoma patients using alemtuzumab, a medication that depletes recirculating T cells from skin, and then analyzed these T cell populations in healthy human skin. All nonrecirculating resident memory T cells (T RM ) expressed CD69, but most were CD4 + , CD103 − , and located in the dermis, in contrast to studies in mice. Both CD4 + and CD8 + CD103 + T RM were enriched in the epidermis, had potent effector functions, and had a limited proliferative capacity compared to CD103 − T RM . T RM of both types had more potent effector functions than recirculating T cells. We observed two distinct populations of recirculating T cells, CCR7 + /L-selectin + central memory T cells (T CM ) and CCR7 + /L-selectin − T cells, which we term migratory memory T cells (T MM ). Circulating skin-tropic T MM were intermediate in cytokine production between T CM and effector memory T cells. In patients with cutaneous T cell lymphoma, malignant T CM and T MM induced distinct inflammatory skin lesions, and T MM were depleted more slowly from skin after alemtuzumab, suggesting that T MM may recirculate more slowly. In summary, human skin is protected by four functionally distinct populations of T cells, two resident and two recirculating, with differing territories of migration and distinct functional activities.
INTRODUCTION
Research in both mice and humans has confirmed that skin and other epithelial barrier tissues are populated by a combination of nonrecirculating resident memory T cells (T RM ) as well as T cells that recirculate in and out of tissues (1, 2) . However, the relative proportions and functional activities of resident and recirculating T cells in skin have never been comprehensively studied, especially in humans. T RM cause psoriasis and mycosis fungoides (MF) and are implicated in a variety of other human autoimmune and inflammatory conditions (3) . A better understanding of resident and recirculating T cells could lead to novel therapies for T cell-mediated inflammatory diseases.
Our previous studies of patients with cutaneous T cell lymphoma (CTCL) found that treatment with alemtuzumab, a humanized anti-CD52 antibody, depleted all circulating T cells and purged the skin over time of recirculating T cells but spared a population of nonrecirculating T RM in the skin (2) . Alemtuzumab depletes T cells in the bloodstream but not in the skin because it depletes by antibodydependent cellular cytotoxicity, requiring the presence of neutrophils and/or natural killer cells, cell types that are rare in human peripheral tissues such as the skin but frequent in the circulation (2, 4) .
In these studies, we have studied resident and recirculating T cell subsets in a human-engrafted mouse model and in human patients with CTCL, using alemtuzumab as a tool to deplete recirculating T cells from skin. This has allowed us to discriminate between resident and recirculating T cell populations in human skin and to study their relative frequencies and effector functions. We find that human skin is protected by two distinct populations of recirculating T cells and two distinct populations of T RM , each with different functional capacities.
RESULTS
Skin T cells in a human-engrafted mouse model recapitulate T cell populations in healthy human skin To selectively study recirculating and resident T cells in human skin in an accessible model, we grafted NSG mice with human neonatal foreskin, infused them intravenously with allogeneic peripheral blood mononuclear cells (PBMCs), allowed a dermatitis to develop, and then treated these mice with alemtuzumab to deplete recirculating T cells from skin (Fig. 1A) . Neonatal foreskin was used in these studies because, based on mouse studies showing that T RM are generated in skin after cutaneous infections, we suspected that neonatal human foreskin would have few T RM (1, 5, 6) . This was in fact the case. Human neonatal foreskin contained resident antigen-presenting cells (APCs) including CD1a + Langerhans cells (LCs) and CD11c + dendritic cells (DCs; Fig. 1 , B and C) but had very few T cells (Fig. 1, C and D ). There were 4-fold more CD11c + DCs than T cells in neonatal foreskin (Fig. 1C ) and 45-fold fewer T cells in foreskin than in healthy adult human skin (Fig. 1D) . Additionally, T cells isolated from foreskin lacked expression of the T RM markers CD69 and CD103, which were robustly expressed by a subset of T cells from adult human skin (Fig. 1E ). Neonatal foreskin was therefore an excellent source of T cell-depleted human skin in which the migration and differentiation of newly generated T RM could be studied. Allogeneic T cells injected intravenously into grafted mice Cryosections of human grafted skin immunostained for CD3 (red) and keratin (green). T cells were evident in both the dermis and the epidermis. The dermoepidermal junction is indicated by a white line. (I) In the absence of infused allogeneic PBMCs, no inflammatory infiltrate was observed and few or no T cells were visualized in skin. (J) CD69 up-regulation preceded CD103 up-regulation in T cells migrating into human skin grafts. Human skin grafts were harvested at the indicated time points and collagenase-digested, and T cells were analyzed for CD69 and CD103 expression by flow cytometry. The mean and SEM of two grafted mice per time point are shown (test: t test). ns, not significant. (K and L) T cell populations in grafted skin recapitulate those observed in adult human skin. T cell expression of T CM (CCR7/L-selectin) and T RM (CD69/CD103) markers as assayed by flow cytometry is shown. T cells were isolated by collagenase digestion from healthy adult human skin (HS) or from skin grafts on PBMCinfused mice. Representative histograms (K) and mean and SEM of expression of CD69 and CD103 are shown. The mean and SEM of three grafts and seven healthy skin donors are shown (test: t test). migrated specifically into the human skin graft and induced an inflammatory dermatitis characterized by migration of T cells into both the dermis and the epidermis (Fig. 1, F to H) . In contrast, mice grafted with human foreskin but not injected intravenously with allogeneic T cells lacked inflammation (Fig. 1I) . T cells were evident within the graft by week 1 after infusion, and the T cell infiltrate was maximal by week 3 ( fig. S1 ). In mice, T RM generated by viral infections with herpes simplex virus (HSV) and vaccinia virus coexpressed CD69 and CD103 (5, 6) . A subset of T cells infiltrating the human skin graft up-regulated CD69 and CD103 after migration into the graft (Fig. 1J) . CD69 was expressed within the first week after T cell entry into the graft, but up-regulation of CD103 was slower and peaked at week 3 (Fig. 1J) . We compared the T cells in foreskin grafts with those isolated from healthy adult human skin, a tissue known to contain both skin-tropic CCR7 + /L-selectin + central memory cells (T CM ) and nonrecirculating T RM (2, 7) . Grafts from mice contained CCR7 + /L-selectin + skin-tropic T CM and T cells that expressed CD69 and CD103 in proportions similar to those isolated from antigen-experienced adult human skin (Fig. 1K) . A population of CD69 + T cells that lacked CD103 expression, a subset not reported in mice, was also observed in skin grafts and in healthy human skin (Fig. 1K ). The percentages of T cells expressing CD69 and CD103 in the grafted skin were not significantly different from those expressed by T cells from healthy adult human skin (Fig. 1L ).
Alemtuzumab depletes recirculating T CM from skin grafts but spares a population of T cells in skin Our previous studies in human CTCL patients treated with alemtuzumab demonstrated that this medication depleted T cells in blood and purged the skin of recirculating T cells over time but spared a population of nonrecirculating T RM in skin (2) . Similar to our results in CTCL patients, treatment of foreskin-grafted, PBMC-injected mice with alemtuzumab depleted circulating T cells from the blood but spared a subpopulation of T cells in skin (Fig. 2, A and B) . In contrast, A-dmDT(390)-bisFv(UCHT1), a recombinant immunotoxin composed of diphtheria toxin conjugated to anti-CD3, completely depleted T cells in both blood and skin (Fig. 2, A and B) . In CTCL patients, alemtuzumab depleted the skin of recirculating CCR7 + /L-selectin + /T CM , a population that is also observed in healthy skin (2, 7) . Likewise, alemtuzumab depleted both CD4 + and CD8 + T CM from skin grafts on human-engrafted mice (Fig. 2, C and D) .
Distinct populations of nonrecirculating T RM exist in human-engrafted mice and human skin Having established that the cell populations in human-engrafted mice were comparable to those in healthy human skin and that alemtuzumab depleted recirculating T cells in this model as it did in human patients ( Figs. 1 and 2 ), we set out to study the nonrecirculating T RM populations left within the human skin grafts after alemtuzumab treatment. The vast majority of T RM remaining in skin after alemtuzumab depletion of recirculating T cells expressed CD69, and a subset coexpressed CD103 (Fig. 3A) . In human-engrafted mice, CD4 + T cells were fourfold more frequent than CD8 + T cells both before and after depletion of recirculating T cells with alemtuzumab, suggesting that CD4 cells predominated in both the recirculating and the resident T cell populations in this model (Fig. 3B) . About half of CD8 + T RM expressed CD103, but most CD4 + T RM did not (Fig. 3C ). When T RM were evaluated as a whole, the most frequent population were CD4 + CD103 − T cells, which made up about 66% of the total T RM population (Fig. 3D) . CD8 + T cells made up 17% of the T RM population, and only 26% of the total T RM population expressed CD103. CD69 + T cells were evident in both the epidermis and the dermis of grafts from alemtuzumab-treated humanengrafted mice, and only a subset of these T cells, in both the epidermis and the dermis, coexpressed CD103 (Fig. 3E) . To confirm these results in human patients, we studied the T cells remaining in the skin of CTCL patients after alemtuzumab therapy. We found that, similar to results in human-engrafted mice, T RM remaining in skin after alemtuzumab virtually all expressed CD69 and a subset of both CD4 and CD8 T cells coexpressed CD103 (Fig. 3F) . In addition, a small population of L-selectin + CCR7
− T cells existed in human-engrafted mice, healthy skin, and the skin of CTCL patients (Fig. 2C and fig. S3 , A, E, and F). These cells were not depleted by alemtuzumab and coexpressed CD69, suggesting that they are T RM (Fig. 2C and fig. S3 , A, E, and F).
Antigen-experienced human skin contains two phenotypically and functionally distinct populations of T RM Studies in human-engrafted mice and alemtuzumab-treated CTCL patients demonstrated that there were two distinct populations of CD69 + nonrecirculating T RM in skin: one that expressed CD103 and one that did not. However, the relative percentages and effector functions of cells in the mouse model and in patients with a T helper 2 (T H 2)-biased T cell lymphoma were unlikely to reflect those observed in healthy human skin (8) (9) (10) (11) . We therefore extracted and studied the T cells from healthy adult human skin, a tissue in which T RM have presumably accumulated over many years of infections and antigen exposures.
In mouse skin, the most frequently observed and well-described T RM subset are intraepithelial CD8 + CD103 + T cells, and T cells of this phenotype have also been observed after HSV infection in humans (5, 6, 12, 13) . To study the location and proportion of T RM in human skin, we enzymatically split skin into epidermis and dermis and isolated the T cell populations by collagenase digestion (Fig. 4 , A to C). CD4 + and CD8 + T cells coexpressing CD69 and CD103 were evident in both the epidermis and the dermis, although CD103 + T RM of both subsets were more frequent in the epidermis. CD69 +
CD103
− T RM were more prevalent in the dermis, and both CD4 + and CD8 + T cells had this phenotype. CD69 − T cells, referred to as recirculating T cells, were the least frequent T cell population in both the epidermis and the dermis (Fig. 4 , B and C).
We next studied the functional capacities of T RM and recirculating subsets from whole skin, epidermis, and dermis. In general, cytokine production by the two distinct T RM subsets was greater than observed in recirculating T cells, consistent with their role as resident immune sentinels (Fig. 4D ). Effector cytokine production by CD103 + T RM also tended to be more robust than in CD103 − T RM , most notably with respect to production of interferon-g (IFN-g), tumor necrosis factor-a (TNFa), and interleukin-22 (IL-22). Together, these results demonstrate that two phenotypically and functionally distinct populations of T RM exist in both the CD4 + and CD8 + T cell compartments in human skin. CD103 + T cells were enriched in the epidermis and had a tendency for increased effector cytokine production, whereas CD103 − T RM were more frequent in the dermis and had slightly lower but still very potent effector functions when compared to recirculating T cells.
To study the relative proliferative capacity of the two T RM subsets in healthy skin, we first isolated T cells from the epidermis and dermis as CD103-enriched and CD103-depleted populations, respectively. T cells isolated from the epidermis retained CD103 expression but rapidly lost functional activity and underwent apoptosis after removal from the skin environment, similar to the behavior of CD103 + T RM isolated from mouse brain after infection with vesicular stomatitis virus (14) (fig. S2, A to E). To study antigen responses and proliferative capacity without removing T cells from skin, we injected stimulatory anti-CD3 and anti-CD28 antibodies or antigen derived from heat-killed Candida albicans or Staphylococcus aureus directly into explants of human skin. Injected skin explants were cultured for 2 weeks, after which T cells were collected. Proliferation was assayed by staining for Ki-67, and cytokine production was assayed by intracellular flow cytometry after short-term stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin ( Fig. 5 ). In both CD4 + and CD8 + T cells, proliferation was greatest in the CD103 − T RM subset in response to both antibody and antigen stimulation, although differences only reached significance in CD4 + T cells (Fig. 5 , A and C). Production of TNFa tended to be greater in the CD103 + population (Fig. 5 , B and D). Together, these studies suggest that CD103 + T RM had superior effector functions but a limited proliferative capacity.
T cell CD103 induction is enhanced by keratinocyte contact, depends on transforming growth factor-b, and is independent of T cell keratinocyte adhesion In mouse models of viral skin infection, CD103 expression by T cells required entry into the epidermis and depended on transforming growth factor-b (TGFb) (15, 16) . In human-engrafted mice, T cells that had migrated into the epidermis had a higher rate of CD103 positivity than dermal T cells (Fig. 6 , A and B). To determine whether keratinocyte contact can induce human T cell CD103 up-regulation, we cultured T cells stimulated with aCD3/aCD2/aCD28 beads on keratinocyte or fibroblast monolayers either in direct contact or separated by transwells. CD103 up-regulation was enhanced by direct contact with keratinocytes ( Fig. 6C) . To determine whether adhesive interactions between T cells and keratinocytes participated in the signaling required for induction of CD103, we included function blocking antibodies against E-cadherin, LFA-1, and b 1 integrins in T cell and keratinocyte monolayer cultures (Fig. 6D ). Blocking adhesive interactions had no effect on CD103 upregulation, but neutralizing antibodies against TGFb decreased CD103 induction. Additional studies in transwells and in direct cocultures demonstrated that neutralization of TGFb decreased the CD103 up-regulation induced by keratinocyte contact and that recombinant human TGFb markedly increased CD103 induction in both the presence and absence of contact with keratinocytes (Fig. 6, E and F) . Although adhesive interactions between keratinocyte E-cadherin and CD103 did not participate in stimulating CD103 induction, these interactions did function to anchor T cells to keratinocyte monolayers.
Human skin also contains two distinct populations of recirculating memory T cells We had previously reported that healthy human skin was patrolled by a skin-tropic population of T CM that coexpressed both skin-homing receptors (CLA/CCR4) and central memory markers (CCR7/L-selectin) and were depleted by alemtuzumab therapy (2) . However, when reviewing our results, we observed that both healthy skin and the skin of CTCL patients contained a distinct population of CCR7 + /L-selectin − T cells (Fig. 7, A − T cells made up a significant proportion of T cells in both healthy skin and CTCL patients (Fig. 7B ). These T cells were depleted in CTCL patients by alemtuzumab therapy, demonstrating that they represent a recirculating T cell population (Fig. 7, A and B) . In mice, CCR7 expression is required for exit from peripheral tissues via lymphatics, and a recirculating population of CD4 + /CCR7 + /L-selectin lo T cells was found in Kaede mice to recirculate out of skin in a CCR7-dependent manner (17) (18) (19) . CCR7 + /L-selectin − cells, which we will refer to as migratory memory T cells (T MM ), were present in similar proportions in both healthy skin and among the benign, nonmalignant T cells in patients with CTCL, and these cells were completely depleted by alemtuzumab therapy (Fig. 7B) . T MM made up the majority of both CD4 + and CD8
+ CLA + skin-tropic T cells in the blood of healthy human donors, confirming that T cells do recirculate between the blood and skin (Fig. 7C, representative histograms in fig. S4 ). We next isolated skin-tropic (CLA + ) T CM , T MM , and effector memory T cells (T EM ) from human blood and compared their relative functional capacities after stimulation with PMA and ionomycin followed by comprehensive cellular phenotype by CyTOF mass cytometry (Fig. 7D) . In general, effector cytokine production by T MM was intermediate between that of T EM and T CM . Production of T H 1, T H 17, and T H 22 proinflammatory effector cytokines was highest in T EM , but T H 2 cytokine production (IL-4 and IL-13) was highest in T CM . TNFa was produced at high levels by all T cell subsets. Although not significantly different, IL-2 production, previously reported as a feature of T CM that may render them resistance to apoptosis, tended to be higher in the recirculating T CM and T MM populations than in T EM (20) .
T MM are associated with the development of expanding skin lesions in patients with CTCL and are depleted from skin more slowly than T CM CLA + skin-tropic CCR7 + /L-selectin − T MM clearly recirculate between human blood and skin, as evidenced by their presence in both sites and their depletion by alemtuzumab in patients with CTCL. T MM leaving skin via the lymphatics would be expected to enter skin-draining lymph nodes and eventually reenter the circulation via the thoracic duct. However, these cells lack L-selectin and likely cannot access lymph nodes from blood the way naïve T cells and T CM are thought to, by migrating across high endothelial venues (21, 22) . Instead, these T cells would be expected to home directly back to skin. To study the biologic behavior of these cells in human beings in vivo, we studied CTCL patients with malignant T cells that expressed markers of T MM . We have previously observed that patients with classic Sézary syndrome, composed of the clinical triad of diffuse erythema of the skin, enlargement of the lymph nodes draining both skin and other organs, and circulating malignant T cells in the blood, have malignant T cells with the phenotype of skin-tropic T CM (2, 23) . CLA + T CM would be expected to recirculate between the skin, blood, and lymph nodes according to our current understanding of trafficking, and this is precisely where malignant T cells accumulate in Sézary patients. Moreover, we found that malignant T cells of a CLA + T CM phenotype induced in patients a diffuse erythema of the skin and that this diffuse erythema was the best clinical predictor of complete remission in response to alemtuzumab therapy ( Fig. 8A) (24) . However, patients have a myriad of clinical presentations, and we have found that some patients present with erythematous skin lesions that have ill-defined borders, in contrast to patients with Sézary syndrome, who present with diffuse erythema, and patients with MF, who present with fixed, recurrent, and sharply demarcated inflammatory skin lesions (Fig. 8) . We found that patients with malignant T cells that had the phenotype of CCR7 + /L-selectin − T MM tended to have only involvement of the lymph nodes draining the skin and to have expanding inflammatory skin lesions with ill-defined borders (Fig.  8, B to D) . In one patient, the malignant T cells in blood and skin were a combination of both T CM and T MM . This patient had a background of diffuse erythema as well as more discrete skin lesions on presentation (Fig. 8E) . After 18 days on alemtuzumab, rebiopsy of the skin demonstrated that T CM had been partially depleted, but large numbers of T MM remained in the skin. This was associated with resolution of the diffuse erythema but persistence of the erythematous skin lesions. Together, the lack of lymph node disease, the clinical appearance of these lesions, and the fact that T CM were depleted more rapidly from the skin than T MM after alemtuzumab therapy suggest that T MM do recirculate between the blood and skin, are excluded from the lymph nodes, and may recirculate more slowly than T CM .
DISCUSSION
The skin surface of a healthy adult human being contains nearly 20 billion diverse memory T cells with potent effector functions (7). Our previous studies in alemtuzumab-treated CTCL patients demonstrated that human skin contains a combination of resident and recirculating memory T cells, but the relative frequencies and functional activities of the subsets remain uncharacterized (2). In the current studies, we used alemtuzumab as a tool to deplete recirculating T cells from skin to discriminate between recirculating and T RM populations.
We developed a human-engrafted mouse model to study human resident and recirculating T cell populations in skin. Immunodeficient mice were grafted with human neonatal foreskin, a tissue that contains resident LCs and DCs but has few T cells. The paucity of resident T cells in the graft allowed us to be more confident that T cells observed in the skin after allogeneic intravenous PBMC infusion were derived from the intravenously injected T cells. T RM are normally generated as a result of cutaneous infections. We took advantage of the fact that graft-resident APCs were likely to activate T cells migrating into the graft from the blood via direct allo-recognition, a direct recognition of major histocompatibility complex (MHC) I and II by allogeneic CD8 + and CD4 + T cells, respectively. Direct allo-recognition induces a robust polyclonal T cell response, engaging up to 10% of T cells (25) . That is, we used the allogeneic T cell response to engage the T cell receptor (TCR) and initiate the T RM differentiation program within grafted skin. We observed the development of CD69 + and CD103 + T cells in grafted skin in proportions that were similar to those in adult human skin. However, antigen recognition of allogeneic tissues is likely ongoing in human-engrafted mice, and some CD103 − T cells may be in the process of transitioning to CD103 + T RM .
We next treated these mice with alemtuzumab to discriminate between recirculating and T RM subsets. Similar to our previous results in CTCL patients treated with alemtuzumab, alemtuzumab purged the skin of recirculating T CM but spared a population of T cells in skin. In contrast, immunotoxin A-dmDT(390)-bisFv(UCHT1), an anti-CD3 recombinant diphtheria immunotoxin currently in trials for the treatment of CTCL, depleted T cells completely in both blood and skin of grafted mice (26) .
We observed that virtually all T cells remaining in the skin of grafted mice after alemtuzumab expressed CD69, and similar results were observed in alemtuzumab-treated CTCL patients. In mice, nonrecirculating T RM generated from experimental infections expressed CD69, and populations of T cells in human peripheral tissues have been shown to express this marker as well (1, 7, 27) . CD69 suppresses the activity of sphingosine 1-phosphate receptor 1 (S1P1), and S1P1 down-regulation in mice was found to be necessary for retention of CD8 + T RM in skin (16, 28) . However, it has never been conclusively demonstrated in humans that CD69 identifies the nonrecirculating T cell pool in peripheral tissues. Our studies in human-engrafted mice and in human patients treated with alemtuzumab demonstrate that CD69 is an excellent marker for nonrecirculating T RM in human skin.
Most of the T RM generated by viral infections in mice are sessile CD8 + T cells expressing CD69 and CD103 localized to the epithelium, although dermal CD4 + T RM with more mobility have also been observed after HSV infection (1, 5, 6, 29) . Our studies in engrafted mice, CTCL patients, and healthy human skin demonstrate that most human skin T RM are dermal CD4 + T cells that lack CD103 expression. However, we do find that CD103 + T cells, both CD4 + and CD8 + , are enriched in the epidermis. With respect to their functional capacities, CD103 + T RM had more potent effector functions but a poorer proliferative capacity. T cells isolated from the epidermis, which are enriched for CD103 + T RM , rapidly underwent apoptosis when removed from the skin microenvironment and had a poor proliferative capacity; these findings are very similar to the behavior of CD103 + T RM isolated from the brains of mice after infection with vesicular stomatitis virus (14) .
Up-regulation of CD103 by skin T cells in mouse models has been shown to occur after entry into the epidermis and to depend on TGFb (15) . A second study suggested that IL-33 and TNFa may also contribute (16) . We observed in human-engrafted mice that T cells that had migrated into the epidermis had higher levels of CD103 than dermal T cells. Hypothesizing that contact with keratinocytes might participate in CD103 up-regulation, we found that direct culture of stimulated blood T cells with keratinocyte monolayers enhanced CD103 expression in a manner that was TGFb-dependent but did not require adhesive interactions between T cells and keratinocytes. Moreover, exogenous TGFb markedly enhanced CD103 induction in the presence or absence of direct keratinocyte contact. Although signaling from integrin and CD103-Ecadherin-mediated adhesive interactions did not enhance CD103 upregulation, CD103-E-cadherin interactions did serve to tether T cells to keratinocyte monolayers. Together, these studies suggest that CD103 in human T cells is up-regulated by TGFb produced within the epidermal compartment. Although adhesive interactions with keratinocytes do not induce CD103 up-regulation, CD103 likely participates in tethering T cells within the epidermal compartment.
In summary, we find that human skin is populated by a combination of CD103 + and CD103 − T RM , with CD4 + T RM predominating. The preponderance of CD4 + T RM in human skin may reflect the diversity of antigen exposures encountered by individuals throughout their lifetimes.
Most mouse models of T RM generation use viruses to induce T RM formation, including HSV and vaccinia infection, and these mice are kept in pathogen-free barrier conditions to prevent other infections (5, 6) . In contrast, our healthy adult human skin donors will have been exposed to a combination of viral, bacterial, fungal, and possibly parasitic infections. It is worth noting that the antigen specificities of human skin T RM are a valuable immunologic record of what infectious pathogens and antigens an individual has been exposed to during his or her lifetime. Moreover, encoded within the cytokine and effector functions of these T cells is a history of how these individuals overcame each pathogen. There are currently no techniques that allow us to extrapolate antigen specificity from the sequences of the TCR. However, once such techniques are developed, we will be able to investigate the immunologic history of an individual from the T cells remaining in their skin. Recent studies in mice showed that skin antigen exposures led individual naïve T cells to differentiate into roughly equal numbers of skin-resident T RM and recirculating T CM , suggesting that immune reactions in skin generate TCR identical resident and recirculating T cell subsets (30) .
We identified recirculating T cell subsets by studying the populations of T cells that were depleted from skin by alemtuzumab. Our previous work in patients with leukemic CTCL (L-CTCL) treated with alemtuzumab found that human skin and the skin of CTCL patients contained a population of T cells that coexpressed both skin-homing addressins (CLA/CC4) and central memory markers (CCR7/L-selectin) (2) . In many patients with L-CTCL, malignant T cells had this phenotype (23) . Alemtuzumab depleted these T cells from blood and purged them from the skin over time as well, confirming that they recirculate. T CM , as first described, were thought to be a subset of T cells that recirculated between the blood and lymph nodes and lacked tissue tropism (20) . However, skin-tropic T CM exist in both the skin and blood in humans and would be expected to recirculate actively between the lymph nodes, blood, and the skin. Indeed, a similar population of recirculating T cells was identified in the skin of Kaede mice (17) . These T cells expressed coexpressed CCR7 and L-selectin at intermediate levels and recirculated between the blood, skin, and both skin-draining and distant lymph nodes. These T cells had quantitatively lower levels of L-selectin expression than those from the circulation, but expression was sufficient to allow these cells to recirculate through noncutaneous, distal lymph nodes (17) . Because these T cells could access systemic lymph nodes, we believe that they represent the analogous population in mice to cells we refer to as skin-tropic T CM .
We also found evidence for an additional population of CCR7 + / L-selectin − recirculating T cells in human skin, which we refer to as T MM . This population of recirculating T cells was poorly reproduced in our engrafted mouse model but was present in the blood and skin of healthy individuals and CTCL patients and was depleted by alemtuzumab therapy. In humans, CLA + T MM were the most prevalent subset of CLA + memory T cells in the blood. T MM would presumably be excluded from lymph nodes draining noncutaneous tissues because they lacked L-selectin. However, they would access skin-draining lymph nodes as they migrated out of the skin into the lymphatics and from there into skin-draining lymph nodes. We found support for this concept in the clinical findings that patients with CTCL and T MM malignant T cells tended to have enlargement of only skin-draining lymph nodes (termed dermatopathic nodes) but lacked diffuse lymph node involvement, a feature often observed in L-CTCL patients with T MM malignancies.
With respect to their functional capacities, T MM were intermediate between T CM and T RM in their production of inflammatory cytokines. We found that T H 2 cytokine production was enriched in recirculating T cells (T MM and T CM ) but that the production of T H 1-, T H 2-, T H 17-, and T H 22-associated inflammatory cytokines was enriched in T EM . IL-2 was expressed at higher levels by recirculating T cells, consistent with a possible role for this cytokine in preventing apoptosis and maintaining cell viability during their turbulent and continual migration through the bloodstream and tissues.
Although the data we have are limited, our findings in human patients treated with alemtuzumab suggest that T MM may recirculate more slowly through skin than T CM . CTCL patients with malignant T cells of a T MM phenotype developed ill-defined but discrete skin lesions, whereas L-CTCL patients with malignant T cells of a T CM phenotype had diffuse, often complete, erythema of the skin (erythroderma). We hypothesize that the diffuse erythema caused by malignant T CM arises from the rapid migration of these cells in and out of skin and also within the skin itself. In contrast, T MM gave rise to ill-defined but discrete skin lesions, consistent with a slower migration of these T cells in and out of skin and within the skin itself. Moreover, in the one patient we were capable of studying, T MM were depleted more slowly from the skin than T CM . However, an alternative explanation may be that T MM may be the subset of T cells that give rise to T RM . In this case, the skin lesions we see developing in these patients may represent T MM differentiating in situ into T RM at the sites. The continued development of new expanding skin lesions in these patients likely results from recirculating T MM entering new areas of skin from the bloodstream and initiating new lesions. Whether the skin lesions generated by T RM represent newly generated T RM or simply a slower migration of T MM through skin remains to be determined. Last, it is not clear why T MM are underrepresented in human-engrafted mice. One possibility is that T MM may be a major source of T RM and are therefore depleted as T RM develop in the skin. A second possibility is that the subset of human T cells may not survive well within the mouse microenvironment.
One caveat to our findings is that although we and other groups studying resident and recirculating T cell populations use designations such as T RM and T CM to describe subsets of T cells, markers such as CD69 and CCR7 that are used to define these putatively stable subsets can change with T cell activation. Additional work will be needed to identify exactly how stable these T cell subsets are and to identify additional, less variable surface markers to identify them.
In summary, we present a thorough characterization of resident and recirculating memory T cells in human skin. We find that two discrete populations of T RM are stationed in human skin, and two distinct populations of T cells recirculate through skin. Each of these subsets has distinct recirculation and functional capacities, and each is likely to play a unique role in protection against known pathogens. Both T RM and recirculating T cells are known to contribute to human diseases. For example, psoriasis is a disorder of dysregulated T RM and L-CTCL represents a malignancy of recirculating T cells (23, (31) (32) (33) . Recent findings in mice that T RM and recirculating T cells have very different patterns of gene expression highlight the fact that these cell types have a very distinct biology (15) . Excepting the current study, the relative proportions of resident and recirculating T cells in human tissues remain uncharacterized. Moreover, the contribution of T RM versus recirculating T cells to most human inflammatory and autoimmune diseases and the effects of anti-inflammatory therapies on these T cell subsets are unknown. A better understanding of these resident and recirculating T cell subsets is therefore critical to understand healthy immune responses and identify therapies that preferentially target pathogenic T cells in autoimmune and inflammatory diseases.
MATERIALS AND METHODS
Study design/experimental design This is an experimental laboratory study performed on human tissue samples. All studies were performed in accordance with the Declaration of Helsinki. Blood from healthy individuals was obtained after leukapheresis, and skin was obtained from healthy patients undergoing cosmetic surgery procedures. Blood and lesional skin from patients with CTCL were obtained from patients seen at the Dana-Farber/Brigham and Women's Cancer Center Cutaneous Lymphoma Program. L-CTCL and MF patients described in this article met the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria for L-CTCL/Sézary syndrome or MF (34) . All tissues were collected with previous approval from the Partners and Dana-Farber Institutional Review Board. Enumeration of T cell subsets in immunofluorescence studies was done in an investigator-blinded fashion.
Mechanistic studies on cells derived from blood and human tissues were performed using in vitro assays without blinding or randomization. Study components were not predefined.
Human-engrafted mouse model Human neonatal foreskins were grafted onto the backs of 6-to 8-weekold nonobese diabetic mice/severe combined immunodeficient/IL-2 receptor g chain null mice (The Jackson Laboratory). One week later, 5 x 10 6 allogeneic PBMCs were injected intravenously after isolation from healthy donors by Ficoll centrifugation. Antibody injections commenced 2 to 4 weeks after PBMC engraftment. Alemtuzumab (2.5 mg) or isotype control (human IgG1, BioLegend) was injected intraperitoneally three times per week for 3 weeks. Anti-CD3 diphtheria toxin [A-dmDT(390)-bisFv(UCHT1), 0.625 mg] or isotype control (human IgG1) was injected intravenously once per day for 4 days. At the conclusion of the experiment, blood and skin grafts were harvested for analysis by flow cytometry, immunofluorescence, and/or H&E staining.
Skin and blood samples
The protocols of this study were performed in accordance with the Declaration of Helsinki and were approved by the Institutional Review Board of the Partners Human Research Committee (Partners Research Management). Skin from healthy patients was obtained from patients undergoing cosmetic surgery procedures, and blood from healthy individuals was obtained as discarded tissue after leukopheresis. Neonatal foreskins were obtained from infants undergoing circumcision at the Brigham and Women's Hospital. Blood and lesional skin from patients with CTCL were obtained from patients seen at the DanaFarber/Brigham and Women's Cancer Center Cutaneous Lymphoma Program. L-CTCL and MF patients described in this article met the WHO-EORTC criteria for CTCL. PBMCs were isolated by Ficoll centrifugation.
T cell isolation from skin Full-thickness human skin samples, fresh or after engraftment on mice, were extensively minced and then incubated for 2 hours at 37°C in RPMI 1640 containing 0.2% collagenase type I (Life Technologies) and deoxyribonuclease I (30 Kunitz units/ml, Sigma-Aldrich). Thereafter, cells were collected by filtering the collagenase-treated tissue through a 40-mm cell strainer. For some experiments, epidermis and dermis were separated by overnight incubation in dispase II (1.4 IU/ml, Roche Diagnostics) at 4°C followed by mechanical separation. Epidermis was then minced and incubated with dispase for an additional 30 min at 37°C with agitation followed by filtration through a 40-mm cell strainer. Dermis was minced and treated with collagenase as per full-thickness skin protocol. Cells from whole skin, dermis, or epidermis were incubated at 37°C for 2 days in Iscove's Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum, penicillin/streptomycin, glutamine, and 2-mercaptoethanol before flow cytometry analysis. When indicated ( fig. S2) , the pan-caspase inhibitor Z-VAD-FMK (R&D Systems) was included at low (10 mM) or high (100 mM) concentrations to inhibit apoptosis.
Flow cytometry
Analysis of T cells was performed using directly conjugated monoclonal antibodies obtained from BD Biosciences, eBioscience, BioLegend, Beckman Coulter, or R&D Systems. Isotype-matched negative control antibodies were used to set the gates for positive staining. For analysis of cytokine production, T cells were stimulated with either control medium or PMA (50 ng/ml) (Sigma-Aldrich) and ionomycin (750 ng/ml) (Life Technologies) plus brefeldin A (10 mg/ml) (BD Biosciences) for 4 hours. Cells were surface-stained, fixed, permeabilized, stained with anti-cytokine antibodies, and examined by flow cytometry. For analysis of proliferation, cells were surface-stained, fixed, permeabilized, stained with anti-Ki-67 antibody, and examined by flow cytometry. Analysis of flow cytometry samples was performed on Becton-Dickinson FACSCanto instruments, and data were analyzed using FACSDiva software (V5.1).
Cryosection immunostaining
Human skin grafts were embedded in optimal cutting temperature (OCT), frozen, and stored at −80°C until use. Cryosections (5 mm) were cut, air-dried, fixed for 5 min in acetone, rehydrated in PBS, and blocked with human IgG (20 mg/ml) (Jackson ImmunoResearch Laboratories) for 15 min at room temperature. Sections were incubated with primary antibody for 30 min and then rinsed three times in PBS/1% bovine serum albumin for 5 min. If necessary, secondary antibody was added for 30 min, followed by three rinses. Sections were mounted using ProLong Gold Antifade with 4′,6-diamidino-2-phenylindole (Life Technologies) and examined immediately by immunofluorescence microscopy. Antibodies were obtained from the following: BioLegend (CD3, CD69), LifeSpan BioSciences (CD103), Abcam (cytokeratin 15), and Jackson ImmunoResearch (secondary antibodies). Sections were photographed using a microscope (Eclipse 6600; Nikon) equipped with a 40×/0.75 objective lens (Plan Fluor; Nikon). Images were captured with a camera (SPOT RT model 2.3.1; Diagnostic Instruments) and were acquired with SPOT 4.0.9 software (Diagnostic Instruments).
Proliferation and cytokine analysis of cells stimulated within explants Punch biopsies (10 mm) of healthy adult skin were injected with 100 ml of PBS (control), a-CD3/a-CD28 antibody mixture (0.5 mg/ml each), or heat-killed S. aureus [10 6 /ml, American Type Culture Collection (ATCC)] or C. albicans (5 × 10 3 /ml, ATCC). Biopsies were floated in 0.4-mm pore size Transwell inserts in X-VIVO 15 medium (Lonza). After 2 weeks, cells that had migrated out of the biopsies were collected, rested overnight in X-VIVO 15 medium, and analyzed for cytokine production and proliferation by flow cytometry as described above. Only cells that had migrated out of the explants were analyzed.
In vitro studies of CD103 regulation To obtain keratinocytes, healthy human skin was separated into epidermis and dermis by incubating with dispase II (1.4 IU/ml) (Roche) in RPMI (Life Technologies) at 4°C for 12 hours. Epidermis was peeled away from the dermis, minced, further digested with dispase (1.4 IU/ml) at 37°C for 30 min, and then filtered in a cell strainer. Keratinocytes were cultured to confluence in 24-well flat-bottomed plates using keratinocyte-SFM (serum-free medium) (Life Technologies). To obtain fibroblasts, the dermis was minced, digested with 0.2% collagenase/deoxyribonuclease (Sigma-Aldrich) at 37°C for 2 hours, and then filtered in a cell strainer. Fibroblasts were cultured to confluence in RPMI supplemented with 15% fetal calf serum (FCS) and epidermal growth factor (10 ng/ml). CD3 + CD4
+ and CD3 + CD8 + T cells were isolated using magnetic separation (negative isolation kits, Miltenyi Biotec) from healthy human PBMCs. CD103 was expressed by a mean 3% of the isolated CD8 T cells, but otherwise, surface expression of CD69 and CD103 was <1% in these T cell fractions. T cells (1 × 10 5 ) were stimulated with aCD3/CD2/ CD28 T cell activation beads (Miltenyi Biotec) with 1:2 ratio for 24 hours (day 0) and then added to keratinocyte or fibroblast monolayers (day 1) in Iscove's modified Dulbecco's medium (Corning) supplemented with 10% FCS and L-glutamine. For indirect cultures, Transwells with 0.4-mm polyester membrane (Corning) were used to separate T cells from fibroblasts and keratinocyte monolayers. Neutralizing antibodies for TGFb (R&D Systems), E-cadherin (Millipore), LFA-1 (BioLegend), and integrin b 1 (R&D Systems) and recombinant human TGFb (R&D Systems) were added to coculture system with a final concentration of 10 mg/ml. T cells were collected by washing on day 6 after starting coculture. Adherent T cells were counted by microscopy and collected by incubating the wells with trypsin/EDTA (Gemini Bio-Products) for 5 min at 37°C.
CyTOF mass cytometry analysis of peripheral blood T cells T cells were isolated from healthy donor PBMCs by depletion of non-T cells using the Pan T Isolation kit and autoMACS separator (Miltenyi Biotec). T cells were pretreated with TAPI-2 (100 mM, Sigma-Aldrich) for 1 hour before stimulation and during the 4 hours of stimulation with PMA/ionomycin plus brefeldin A to prevent stimulation-induced cleavage of L-selectin (35) . After stimulation, T cells were stained with surface marker metal-conjugated antibodies (MCAs; Fluidigm Inc.) at concentrations found to be effective in previous antibody tests. After surface staining, cells were fixed, permeabilized, and stained with MCA intracellular antibodies for 30 min at room temperature. The cells were then labeled overnight at 4°C with 125 nM DNA intercalator (Fluidigm Inc.). Finally, the cells were diluted to the appropriate concentration in distilled water containing 10% EQ Four Element Calibration Beads (Fluidigm Inc.) to achieve an acquisition rate of <500 events per second on the CyTOF2 instrument using the recommended default settings for the CyTOF2 (Fluidigm Inc.). CyTOF data were normalized to the beads through the CyTOF2 software after acquisition without bead removal and using default settings (Fluidigm Inc.). After built-in cellidentifying software created an FCS file, CyTOF data were analyzed in a manner similar to standard flow cytometry analysis by FCS Express software 4.0 (De Novo Software) using DNA content and normalization beads to identify single-cell events.
Statistical analyses
Primary methods of data analysis included descriptive statistics (means, medians, and SD). Differences between two sample groups were detected using the one-tailed Wilcoxon-Mann-Whitney test, a = 0.05. For comparisons of multiple groups, a Kruskal-Wallis one-way ANOVA with a Bonferroni-Dunn's posttest for multiple means test was used, a = 0.05.
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